Spruce biosciences reports second quarter 2021 financial results and provides corporate updates

San francisco--(business wire)--spruce biosciences, inc. (nasdaq: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended june 30, 2021 and provided a corporate update. “as we continue to progress the execution of the cahmelia clinical program in adults with classic congenital adrenal hyperplasia (cah), we were also pleas
SPRB Ratings Summary
SPRB Quant Ranking